Home > Oncology > ELCC 2022 > Early-Stage Non-Small Cell Lung Cancer > Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC

Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC

Presented By
Dr Chao Lyu, Beijing Cancer Hospital, China
Conference
ELCC 2022
Trial
Phase 2, NEOS
Doi
https://doi.org/10.55788/6dc895bd
The final results of the phase 2 NEOS trial demonstrated promising efficacy and good tolerability of neoadjuvant treatment with osimertinib in patients with stage II–IIIB, EGFR-mutated non-small cell lung cancer (NSCLC). Osimertinib is a third-generation tyrosine kinase inhibitor approved for adjuvant therapy in patients with stage IB–IIIA, EGFR-mutated NSCLC. The Chinese, prospective, multicentre, single-arm, phase 2 NEOS trial (ChiCTR1800016948) aimed to determine the safety and efficacy of osimertinib as neoadjuvant therapy for the treatment of patients with resectable EGFR-mutated NSCLC. NEOS enrolled a total of 40 patients with stage II–IIIB, EGFR-mutated NSCLC. Participants were treated with osimertinib 80 mg once daily for 6 weeks followed by surgical resection; 38 participants completed neoadjuvant osimertinib, 32 participants underwent surgery (6 patients refused, 1 because of treatment-related adverse ev...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on